2022年度肺癌领域重要临床研究进展

doi:10.19401/j.cnki.1007-3639.2023.03.004

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (3): 218-227.doi: 10.19401/j.cnki.1007-3639.2023.03.004

2022年度肺癌领域重要临床研究进展

苏春霞(), 周彩存()

同济大学附属上海市肺科医院肿瘤科，上海 200433

收稿日期:2023-01-18 修回日期:2023-03-02 出版日期:2023-03-30 发布日期:2023-04-17
通信作者: 周彩存（ORCID: 0000-0002-1072-9941），博士，主任医师、教授。
作者简介:苏春霞（ORCID: 0000-0003-1632-9487），博士，主任医师、教授。同济大学附属上海市肺科医院肿瘤科主任医师、教授、博士研究生导师。长期从事肺部肿瘤的临床诊治及研究工作，聚焦肺癌免疫治疗、抗血管生成治疗及耐药机制与对策、肺癌精准靶向治疗及全程管理策略。主持国家自然科学基金3项、中国科学技术协会“十三五”前期研究课题1项、申康新兴前沿联合攻关项目1项、上海市科学技术委员会面上项目3项、上海市卫生健康委员会科研项目1项等课题10余项；作为主要研究者或次要研究者主持或参与国际及国内多中心临床研究20余项。曾获国家科技进步奖二等奖、上海市科学技术进步奖一等奖、上海市科学技术普及二等奖、上海市抗癌科技奖（科普奖）、上海市科普教育创新二等奖、上海市抗癌科技奖一等奖、第四届上海“医树奖”临床医学科技创新奖一等奖等。入选上海市优秀学术带头人，获上海市优秀杰出青年医师、上海市五四青年奖章、国之名医优秀风范奖等荣誉称号。主编或主译专著7部，获得专利2项。以第一作者或通信作者（含共同）在Lancet Respiratory Medicine、Journal of Thoracic Oncology、European Journal of Cancer、International Journal of Cancer、Cancer Immunology Immunotherapy、Translational Lung Cancer Research、Lung Cancer等期刊发表论文50余篇。
基金资助:
国家自然科学基金面上项目(82072568)

Important clinical research progress in lung cancer in 2022

SU Chunxia(), ZHOU Caicun()

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China

Received:2023-01-18 Revised:2023-03-02 Published:2023-03-30 Online:2023-04-17
Contact: ZHOU Caicun

摘要/Abstract

摘要：

肺癌仍然是中国发病率和死亡人数最高的恶性肿瘤，其中，非小细胞肺癌（non-small cell lung cancer，NSCLC）约占80%以上。围手术期NSCLC辅助免疫治疗和新辅助免疫治疗相关临床研究推陈出新。靶向治疗方面，罕见及难治性肺癌靶点探索和药物研发持续推进，抗体药物偶联物的研发方兴未艾，有望开辟肺癌诊疗新途径。NSCLC诊疗逐渐步入精准化、规范化时代。在晚期NSCLC患者免疫治疗方面，免疫联合新方案有望进一步提高疗效。本文回顾2022年度NSCLC治疗领域的临床进展，阐述现阶段面临的问题和挑战，并探讨未来发展方向。

关键词: 非小细胞肺癌, 围手术期, 靶向治疗, 免疫治疗

Abstract:

Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Clinical studies related to adjuvant immunotherapy and neoadjuvant immunotherapy in perioperative NSCLC have been updated. In terms of targeted therapy, the research and development of drugs for rare and difficult-to-treat targets continues to be hot, and the research and development of antibody-drug conjugate gradually becomes hot, which is expected to open a new track for the diagnosis and treatment of lung cancer. Rare target diagnosis and treatment of NSCLC has gradually entered an era of precision and standardization. In terms of immunotherapy for patients with advanced NSCLC, the new regimen of combined immunotherapy is expected to further improve the efficacy. This review, with the focus on advanced NSCLC, summarized the development of NSCLC, discussed current problems and challenges, and proposed prospects on future directions.

Key words: Non-small cell lung cancer, Perioperative period, Targeted therapy, Immunotherapy

中图分类号:

R734.2

苏春霞, 周彩存. 2022年度肺癌领域重要临床研究进展[J]. 中国癌症杂志, 2023, 33(3): 218-227.

SU Chunxia, ZHOU Caicun. Important clinical research progress in lung cancer in 2022[J]. China Oncology, 2023, 33(3): 218-227.

参考文献 39

[1]	WAKELEE H, ALTORKI N, FELIP E, et al. PL03.09 IMpower010: overall survival interim analysis of a phase Ⅲ study of atezolizumab vs best supportive care in resected NSCLC[J]. J Thorac Oncol, 2022, 17(9): S2.
[2]	O’BRIEN M, PAZ-ARES L, MARREAUD S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage ⅠB-ⅢA non-small cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial[J]. Lancet Oncol, 2022, 23(10): 1274-1286. doi: 10.1016/S1470-2045(22)00518-6
[3]	PAZ-ARES L, O’BRIEN M E R, MAUER M, et al. Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase Ⅲ EORTC-1416-LCG/ETOP 8-15-PEARLS/KEYNOTE-091 study[J]. Ann Oncol, 2022, 33(4): 451-453. doi: 10.1016/j.annonc.2022.02.224
[4]	PASSARO A. Invited Discussant 1529MO, 930MO and 933MO[EB/OL]. (2022-09-12)[2023-02-02]. https://oncologypro.esmo.org/meeting-resources/esmo-congress/invited-discussant-1529mo-930mo-and-933mo.
[5]	PROVENCIO M, SERNA R, NADAL E, et al. PL03.12 progression free survival and overall survival in NADIM Ⅱ study[J]. J Thorac Oncol, 2022, 17(9): S2-S3.
[6]	TSUBOI M, WU Y L, GROHE C, et al. Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage ⅠB-ⅢA non-small cell lung cancer (NSCLC): updated results from ADAURA[J]. Ann Oncol, 2022, 33: S1413-S1414.
[7]	YUE D S, XU S D, WANG Q, et al. Updated overall survival and exploratory analysis from randomized, phase Ⅱ EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage ⅢA epidermal growth factor receptor + non-small cell lung cancer[J]. J Clin Oncol, 2022, 40(34): 3912-3917. doi: 10.1200/JCO.22.00428
[8]	ZHONG W Z, CHEN K N, CHEN C, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage ⅢA-N2 EGFR-mutant non-small cell lung cancer (EMERGING-CTONG 1103): a randomized phase Ⅱ study[J]. J Clin Oncol, 2019, 37(25): 2235-2245.
[9]	LYU C, FANG W, JIAO W, et al. Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage Ⅱ-ⅢB lung adenocarcinoma (NEOS): updated results[J]. Ann Oncol, 2022, 33: S71-S72.
[10]	TSUBOI M, WEDER W, ESCRIU C, et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small cell lung cancer: NeoADAURA[J]. Future Oncol, 2021, 17(31): 4045-4055. doi: 10.2217/fon-2021-0549
[11]	FORDE P M, SPICER J, LU S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21): 1973-1985. doi: 10.1056/NEJMoa2202170
[12]	SHI Y K, CHEN G, WANG X, et al. Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase Ⅲ study (FURLONG)[J]. Ann Oncol, 2022, 33: S27.
[13]	YUANKAI SHI, MD, et al. Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR-mutated NSCLC: results from the FURLONG study[J]. J Thorac Oncol, 2022, 17(11): 1297-1305. doi: 10.1016/j.jtho.2022.07.1143
[14]	GOLDMAN J, HUANG H K T, CUMMINGS A, et al. MA07.05 phase 1b/2 study of combined HER inhibition in refractory EGFR-mutated metastatic non-small cell lung cancer (NSCLC)[J]. J Thorac Oncol, 2022, 17(9): S68-S69.
[15]	ALEXANDRA YU H, TAN D S W, SMIT E F, et al. Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (ins20)[J]. J Clin Oncol, 2022, 40(16_suppl): 9007. doi: 10.1200/JCO.2022.40.16_suppl.9007
[16]	16 ZHOU C C, RAMALINGAM S S, KIM T M, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial[J]. JAMA Oncol, 2021, 7(12): e214761.
[17]	WANG M, YANG J C H, MITCHELL P, et al. Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: preliminary analysis of WU-KONG6, the first pivotal study[J]. Ann Oncol, 2022, 33: S1003-S1004.
[18]	ZHOU Q, LI J, WANG J, et al. EP08.02-063 SANOVO: a phase 3 study of savolitinib or placebo in combination with osimertinib in patients with EGFR-mutant and MET overexpressed NSCLC[J]. J Thorac Oncol, 2022, 17(9): S429.
[19]	SWAIN S M, SHASTRY M, HAMILTON E. Targeting HER2-positive breast cancer: advances and future directions[J]. Nat Rev Drug Discov, 2023, 22(2): 101-126. doi: 10.1038/s41573-022-00579-0
[20]	GOLDMAN J W, HORINOUCHI H, CHO B C, et al. Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2022, 40(16_suppl): 9013. doi: 10.1200/JCO.2022.40.16_suppl.9013
[21]	LI B, SMIT E F, GOTO Y, et al. Primary data from DESTINY-Lung01: a phase 2 trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)[C]. ESMO Congress, 2021.
[22]	LI B T, SMIT E F, GOTO Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small cell lung cancer[J]. N Engl J Med, 2022, 386(3): 241-251. doi: 10.1056/NEJMoa2112431
[23]	FDA. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer[EB/OL]. (2022-08-16)[2023-02-02]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung.
[24]	ROMÁN M, BARAIBAR I, LÓPEZ I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target[J]. Mol Cancer, 2018, 17(1): 33. doi: 10.1186/s12943-018-0789-x
[25]	RECK M, CARBONE D P, GARASSINO M, et al. Targeting KRAS in non-small cell lung cancer: recent progress and new approaches[J]. Ann Oncol, 2021, 32(9): 1101-1110. doi: 10.1016/j.annonc.2021.06.001
[26]	JÄNNE P A, RIELY G J, GADGEEL S M, et al. Adagrasib in non-small cell lung cancer harboring a KRAS G12C mutation[J]. N Engl J Med, 2022, 387(2): 120-131. doi: 10.1056/NEJMoa2204619
[27]	SABARI J K, VELCHETI V, SHIMIZU K, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRAS G12C-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2022, 28(15): 3318-3328. doi: 10.1158/1078-0432.CCR-22-0383
[28]	FALCHOOK G, LI B T, MARRONE K A, et al. OA03.03 sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors[J]. J Thorac Oncol, 2022, 17(9): S8.
[29]	ZHOU C, LU Y, KIM S W. Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK + non-small cell lung cancer (NSCLC): 5-year update from the phase Ⅲ ALESIA study[J]. Ann Oncol, 2022, 33: S1563.
[30]	CAMIDGE D R, DZIADZIUSZKO R, PETERS S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase Ⅲ ALEX study[J]. J Thorac Oncol, 2019, 14(7): 1233-1243. doi: 10.1016/j.jtho.2019.03.007
[31]	ZHANG L, FANG W, MIN J, et al. Envonalkib vs crizotinib in treatment-naïve advanced ALK-positive NSCLC: a randomized, multicenter, phase Ⅲ trial[J]. Ann Oncol, 2022, 33: S1564-S1565.
[32]	LEE S M, SCHULZ C, PRABHASH K, et al. IPSOS: Results from a phase Ⅲ study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen[J]. Ann Oncol, 2022, 33: S1418-S1419.
[33]	GARASSINO M C, GADGEEL S M, SPERANZA G, et al. KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC[J]. Ann Oncol, 2022, 33: S992-S993.
[34]	NOVELLO S, KOWALSKI D M, LUFT A, et al. Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer: 5-year update of the phase Ⅲ KEYNOTE-407 study[J]. J Clin Oncol, 2023. [Online ahead of print]
[35]	JOHNSON M, CHO B C, LUFT A, et al. Durvalumab (D)±tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)[J]. Ann Oncol, 2022, 33: S1424-S1425.
[36]	RECKAMP K L, REDMAN M W, DRAGNEV K H, et al. Phase Ⅱ randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small cell lung cancer previously treated with immunotherapy-lung-MAP S1800A[J]. J Clin Oncol, 2022, 40(21): 2295-2306. doi: 10.1200/JCO.22.00912
[37]	PROF, SHUN, LU, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(9): 1167-1179. doi: 10.1016/S1470-2045(22)00382-5
[38]	LEVY B, PAZ-ARES L, RIXE O, et al. MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC[J]. J Thorac Oncol, 2022, 17(9): S91.
[39]	RECKAMP K L, REDMAN M W, DRAGNEV K H, et al. Overall survival from a phase Ⅱ randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: lung-MAP nonmatched substudy S1800A[J]. J Clin Oncol, 2022, 40(suppl 16): 9004. doi: 10.1200/JCO.2022.40.16_suppl.9004

2022年度肺癌领域重要临床研究进展

Important clinical research progress in lung cancer in 2022

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 39

相关文章 15

编辑推荐

Metrics

本文评价

[1]	田熙, 徐文浩, 朱殊璇, 艾合太木江·安外尔, 宿佳琦, 叶世琪, 瞿元元, 施国海, 张海梁, 叶定伟. 2022年度肾细胞癌基础研究及临床诊疗新进展[J]. 中国癌症杂志, 2023, 33(3): 191-200.
[2]	曹晓珊, 丛斌斌. 三阳性乳腺癌内分泌治疗联合靶向治疗的研究进展[J]. 中国癌症杂志, 2023, 33(3): 288-292.
[3]	邵志博, 杨犇龙, 吴炅. 2022年中国乳腺癌重要临床试验成果及最新进展[J]. 中国癌症杂志, 2023, 33(2): 103-109.
[4]	郭晴, 张剑. HER2低表达乳腺癌的靶向治疗研究进展[J]. 中国癌症杂志, 2023, 33(2): 181-190.
[5]	陈瑛瑶, 储香玲, 俞昕, 苏春霞. 免疫检查点抑制剂疗效相关预测模型的研究进展[J]. 中国癌症杂志, 2023, 33(1): 61-70.
[6]	肖玉铃, 朱秀之, 江一舟, 邵志敏. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022, 32(8): 669-679.
[7]	周文斌, 谢晖, 丁强, 王水. 在乳腺癌局部精准治疗中的新进展：联合免疫治疗未来可期[J]. 中国癌症杂志, 2022, 32(8): 698-704.
[8]	何丽媛, 王玉栋. ALK激酶域耐药突变的研究进展及未来应对策略[J]. 中国癌症杂志, 2022, 32(8): 736-746.
[9]	洪雅萍, 黄韵坚, 黄漳州, 陈胜佳, 钟巧凤, 曾洪福, 庄武. EGFR突变的晚期非小细胞肺癌患者接受一代TKI靶向治疗的效果及预后预测因子分析[J]. 中国癌症杂志, 2022, 32(7): 624-634.
[10]	苏春霞, 周彩存. 晚期非小细胞肺癌免疫治疗现状及未来方向[J]. 中国癌症杂志, 2022, 32(6): 478-486.
[11]	虞思来, 倪建佼, 朱正飞. 免疫治疗时代不可手术局部晚期非小细胞肺癌的治疗：现状与展望[J]. 中国癌症杂志, 2022, 32(6): 487-498.
[12]	李小秋, CD30阳性淋巴瘤病理专家组. CD30在淋巴瘤中的表达及检测：现状与挑战[J]. 中国癌症杂志, 2022, 32(6): 512-518.
[13]	宿佳琦, 徐文浩, 田熙, 艾合太木江·安外尔, 瞿元元, 施国海, 张海梁, 叶定伟. 肾透明细胞癌联合免疫治疗新策略——有氧糖酵解的研究进展及展望[J]. 中国癌症杂志, 2022, 32(4): 287-297.
[14]	傅圆圆, 侯润萍, 傅小龙. 基于胸部CT预测早期非小细胞肺癌淋巴道或血道转移风险的研究进展[J]. 中国癌症杂志, 2022, 32(4): 343-350.
[15]	陈光亮, 吴方恬, 曹军宁. 非特指EBV阳性弥漫大B细胞淋巴瘤的研究进展[J]. 中国癌症杂志, 2022, 32(3): 258-267.